Skip to main content
twitter
facebook
youtube
instagram
Donate to EGFR Resisters to Continue Vital Research
Hit enter to search or ESC to close
Close Search
Menu
HOME
WHO WE ARE
LEADERSHIP
OUR MISSION
EXPERT PARTNERSHIPS
YOUNG INVESTIGATORS
MEMBERSHIP
JOIN
PROJECTS & EDUCATION
ABOUT EGFR
PROJECT PRIORITY
ANNUAL RESEARCH SUMMIT
RESEARCH AWARDS
EDUCATION
NEWS
ALL NEWS
ADVOCACY
COPING & STORIES
RESEARCH & TREATMENT
SOCIAL MEDIA
INSTAGRAM
FACEBOOK
TWITTER
OUR YouTube CHANNEL
ALLIANCES & RESOURCES
MONTHLY NEWSLETTERS
LUNG CANCER ADVOCACY
BIOMARKER GROUPS
CONTACT US
DONATE
Research
Treatments
Osimertinib + Bevacizumab for EGFR+ NSCLC: Another negative trial
By
laurabbook@gmail.com
No Comments
*September 2021*
GIVE TODAY
DONATE
Categories
Advocacy
26
Coping With Cancer
38
Funding
9
Partners
2
Research
292
Resources
1
Stories
7
Treatments
280
STAY CONNECTED
VIEW NEWSLETTERS
You Might Like
Passing of The Baton—On the Death of Patient Research Advocates
February 3, 2023
Making the Most of Time Between Scans
February 3, 2023
New Treatment Options for Stage IV NSCLC With Driver Alterations
February 3, 2023
Antibody-drug conjugates in lung cancer: dawn of a new era?
February 3, 2023
Spira Highlights Key Advancements Across the NSCLC Treatment Paradigm in 2022
February 6, 2023
BECOME A MEMBER
JOIN
Share
Tweet
Share
Pin
Close Menu
HOME
WHO WE ARE
LEADERSHIP
OUR MISSION
EXPERT PARTNERSHIPS
YOUNG INVESTIGATORS
MEMBERSHIP
JOIN
PROJECTS & EDUCATION
ABOUT EGFR
PROJECT PRIORITY
ANNUAL RESEARCH SUMMIT
RESEARCH AWARDS
EDUCATION
NEWS
ALL NEWS
ADVOCACY
COPING & STORIES
RESEARCH & TREATMENT
SOCIAL MEDIA
INSTAGRAM
FACEBOOK
TWITTER
OUR YouTube CHANNEL
ALLIANCES & RESOURCES
MONTHLY NEWSLETTERS
LUNG CANCER ADVOCACY
BIOMARKER GROUPS
CONTACT US
DONATE
twitter
facebook
youtube
instagram